Wearable Sensor-Based Assessments for Remotely Screening Early-Stage Parkinson's Disease

Sensors (Basel). 2024 Aug 30;24(17):5637. doi: 10.3390/s24175637.

Abstract

Prevalence estimates of Parkinson's disease (PD)-the fastest-growing neurodegenerative disease-are generally underestimated due to issues surrounding diagnostic accuracy, symptomatic undiagnosed cases, suboptimal prodromal monitoring, and limited screening access. Remotely monitored wearable devices and sensors provide precise, objective, and frequent measures of motor and non-motor symptoms. Here, we used consumer-grade wearable device and sensor data from the WATCH-PD study to develop a PD screening tool aimed at eliminating the gap between patient symptoms and diagnosis. Early-stage PD patients (n = 82) and age-matched comparison participants (n = 50) completed a multidomain assessment battery during a one-year longitudinal multicenter study. Using disease- and behavior-relevant feature engineering and multivariate machine learning modeling of early-stage PD status, we developed a highly accurate (92.3%), sensitive (90.0%), and specific (100%) random forest classification model (AUC = 0.92) that performed well across environmental and platform contexts. These findings provide robust support for further exploration of consumer-grade wearable devices and sensors for global population-wide PD screening and surveillance.

Keywords: Parkinson’s disease; digital biomarkers; early detection; feature engineering; gait analysis; mobile health technologies; phonation; remote monitoring; wearable sensors.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Biosensing Techniques / instrumentation
  • Biosensing Techniques / methods
  • Female
  • Humans
  • Longitudinal Studies
  • Machine Learning
  • Male
  • Middle Aged
  • Parkinson Disease* / diagnosis
  • Wearable Electronic Devices*

Grants and funding

Funding for the study was contributed by Biogen, Takeda, and the members of the Critical Path for Parkinson’s Consortium 3DT Initiative, Stage 2.